Glycosylation News and Research

RSS

SARS-CoV-2 infection increases risk of severe COVID-19 in pregnant women, newborns

Recent analyses indicate that pregnant women and newborns may face elevated risks of developing more severe cases of COVID-19 following SARS-CoV-2 infection.

24 Dec 2020

Long-range allosteric influences on SARS-COV-2-ACE2 stability and detachment

The COVID-19 pandemic is caused by SARS-CoV-2, a novel beta-coronavirus which has numerous spike proteins on its membrane.

3 Dec 2020

N-Glycosylation sites may contribute to spike-mediated invasion by SARS-CoV-2

The sugar residues decorating the spike (S) protein of SARS-CoV-2 are essential to the viral-receptor binding.

3 Dec 2020

Ipom-F inhibits SARS-CoV-2 infection in vitro

An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.

27 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Severe COVID-19 complications linked to gut barrier breakdown

A new study claims that severe COVID-19 is caused by a positive feedback loop triggered by systemic inflammation and mediated by abnormal gut permeability. This finding could potentially help open up new avenues of treatment.

18 Nov 2020

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.

9 Nov 2020

Research sheds light on how encapsulated viruses hijack protein production systems

Researchers from the Universities of Melbourne, York, Warwick and Oxford have shed light on how encapsulated viruses like hepatitis B, dengue and SARS-CoV-2 hijack the protein manufacturing and distribution pathways in the cell - they have also identified a potential broad spectrum anti-viral drug target to stop them in their tracks.

6 Nov 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

Researchers apply a novel technique to improve understanding of liver disease, immune activation

Human cells are encased by a membrane coated with diverse sugar molecules known as glycans. These glycans play many roles in health and disease, making them important to understand.

20 Oct 2020

Molecular simulations reveal detailed structure and dynamics of SARS-CoV-2 spike protein

Recently, researchers reported a study in which they analyzed the structure and dynamics of the spike protein using multiple molecular dynamic simulations. Their study is published on the preprint server bioRxiv.

19 Oct 2020

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Researchers at The Medical Research Council Laboratory of Molecular Biology have conducted a study showing how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein interacts with host cell factors in ways that promote the formation of syncytia.

13 Oct 2020

Why blood type O might lower risk for SARS-CoV-2 infection

The author hypothesizes that people with non-O blood groups may have highest contact with the SARS-CoV-2 virus via the formation of in intermediate structure, resulting in possibly higher infection rates and more severe symptoms.

12 Oct 2020

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Researchers from the Japan Advanced Institute of Science and Technology (JAIST) and Ishikawa Prefectural University, Japan, recently attempted to synthesize the ORF8 protein with the help of a chemical-inducible protein production system using tobacco BY-2 cells. This study has been published demonstrated in the preprint server, bioRxiv.

9 Oct 2020

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

Development of a coarse-grained model of SARS-CoV-2 virion

A team of scientists of the University of Chicago and the University of California San Diego has developed a coarse-grained (CG) model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virion. The model can be used as a valuable resource to perform multiscale simulations of the SARS-CoV-2 virion. The study is currently available on the bioRxiv* preprint server.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).